Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma

Introduction Enfortumab vedotin is an antibody‐drug conjugate targeting Nectin‐4 for the treatment of advanced urothelial carcinoma in patients previously treated with platinum‐containing chemotherapy and immune checkpoint inhibitors. Common adverse events include rashes, peripheral neuropathy, and...

Full description

Bibliographic Details

Main Authors:	Kazuki Yanagida, Taketo Kawai, Toyoshi Seito, Kensuke Matsumoto, Tomoyuki Kaneko, Tohru Nakagawa
Format:	Artigo
Language:	Inglês
Published:	Wiley 2024-07-01
Series:	IJU Case Reports
Subjects:	eltrombopag enfortumab vedotin myelodysplastic syndrome urothelial carcinoma
Online Access:	https://doi.org/10.1002/iju5.12734
Tags:	Add Tag No Tags, Be the first to tag this record!